The first of this two article series quantified and explained out of pocket (OOP) cost in the Australian Health system. Some areas of OOP costs are acceptable and there is no need to intervene. OOP costs for non PBS pharmaceuticals, for example, largely reflect discretionary spending on products with little proven impact on health outcomes. … Continue reading ANDREW PESCE. Patient Gap payments and Out of Pocket Costs. What needs to be done? Part 2… Continue reading »